Renaissance Technologies’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Renaissance Technologies’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-243,875	Closed	-$26.2M	–	4406
2023 Q1	$26.2M	Buy	243,875 +1,300	+0.5%	+$150K	0.03%	591
2022 Q4	$26.7M	Buy	242,575 +132,300	+120%	+$8.58M	0.04%	585
2022 Q3	$6.51M	Buy	110,275 +60,675	+122%	+$2.78M	0.01%	1286
2022 Q2	$1.4M	Buy	+49,600	New	+$1.44M	﹤0.01%	2473

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Renaissance Technologies's RXDX Position: Q2 2023 in Review

Renaissance Technologies sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 243,875 shares — an estimated $26.2M sold.

Renaissance Technologies first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $26.7M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Renaissance Technologies reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 243,875 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $26.2M.
Renaissance Technologies first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Renaissance Technologies's Prometheus Biosciences, Inc. Common Stock position peaked at $26.7M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.